Doxorubicin hydrochloride is approved for use with other drugs as adjuvant therapy for breast cancer that has spread to the lymph nodes, including cancer that is HER-2 positive or has spread after surgery.
In addition to the uses that have been approved by the FDA, doxorubicin hydrochloride is sometimes used alone or with other drugs to treat other types of cancer. The drug continues to be studied in the treatment of many types of cancer.
In long-term survivors of childhood cancer, cardiovascular disease is a leading cause of early death from non-cancer causes.
Multi-Walled Carbon Nanotubes is the name that is derived from their structure and walls are formed by one atom thick sheet of carbon.
Some patients with breast cancer receive chemotherapy before the tumor is removed with surgery. This approach, called 'neoadjuvant' therapy, helps to reduce the size of the tumor to facilitate breast-conserving surgery, and can even eradicate the tumor, leaving few or no cancerous cells for the surgeon to remove.
Multi-Walled Carbon Nanotubes (MWCNTs) are characterized by walls formed by a one atom thick sheet of carbon.
A technique to get more information from the blood of cancer patients than previously possible has been developed.
In this interview, Émilie Beaulieu Ouellet, Application Scientist for life science imaging at Photon Etc talks to New-Medical about their range of preclinical infrared imagers and how they can allow cancer detection.
One of the most successful techniques to combat multidrug resistance in cancer cells is the downregulation of those genes responsible for drug resistance.
Mannose is a sugary nutritional supplement that has shown promise in slowing down the growth of certain cancers in laboratory mice. The results of the five year-long study from Glasgow were published in the latest issue of the journal Nature.
Mannose sugar, a nutritional supplement, can both slow tumor growth and enhance the effects of chemotherapy in mice with multiple types of cancer.
Mannose, a type of sugar, has been shown to slow tumor growth and enhance chemotherapy in mouse models of certain cancers.
A new study by Washington State University researchers suggests that a protein called CDK2 plays a critical role in heart damage caused by doxorubicin, a commonly used chemotherapy drug.
Nanosystems that deliver anticancer drugs or imaging materials to tumors are showing significant progress, particularly those that respond to tumor-related stimuli, according to a review published in the journal Science and Technology of Advanced Materials.
With a pair of RO1 grants from the National Institutes of Health, pain researcher Daniela Salvemini, Ph.D., will embark on two new research projects, studying chemotherapy-induced cognitive impairment, or "chemo brain," symptoms and unwanted side effects of opioids.
Sarcoma patients show great openness to the use of complementary alternative medicines (CAMs) for supportive care, but they are poorly informed about safety issues and risk of interactions with anti-cancer drugs, a study to be presented at ESMO 2018 reported.
Chemotherapy drugs to treat breast cancer may promote muscle mitochondrial dysfunction, according to new research. Dysfunctional mitochondria, the energy centers of the cells, may contribute to fatigue and weakness that some people with breast cancer experience through the course of disease treatment.
Scientists at the University of Toronto's Leslie Dan Faculty of Pharmacy have seen remarkable success combining tumor modulating nanoparticles with doxorubicin to enhance chemotherapy response in pre-clinical model breast cancer.
Approximately 10-20 percent of diagnosed breast cancers are found to be triple-negative, meaning the breast cancer cells test negative for estrogen and progesterone receptors as well as HER2 receptors, genes that can play a role in the development of breast cancer.
Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.
Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval from the Japanese Ministry of Health, Labour and Welfare for ADCETRIS (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine as a frontline treatment option for CD30-positive Hodgkin lymphoma patients in Japan.
Among a small cohort of patients with HIV-associated Kaposi's sarcoma treated with immune checkpoint inhibitors, more than 65 percent had partial or complete remission.